OBJECTIVES This study sought to validate exercise capacity (EC) as a surrogate for mortality, hospitalization, and health-related quality of life (HRQOL).
Administration (4) . Although it is a measure of function and clinical benefit, EC is a surrogate endpoint rather than a final patient-relevant outcome, such as mortality, hospital admission, or health-related quality of life (HRQOL).
For a surrogate endpoint to be considered a valid surrogate endpoint (i.e., an adequate substitute for the final outcome), several levels of evidence must be provided (5) . First, there needs to be biological plau- Epidemiological studies have shown that a 1.0 metabolic equivalent (MET) (1 MET ¼ 3.5 ml/kg/min) increase in VO 2 peak translates into a 12% risk reduction in mortality in individuals with existing cardiovascular disease, including HF (6) . However, to our knowledge no previous study has assessed the validity of EC as a surrogate endpoint for HF in a RCT setting.
Using RCTs of exercise-based cardiac rehabilitation (CR) in patients with HF, we sought to address the following 2 research questions: 1) is there an association between the intervention effect of CR in HF on EC, and each of mortality, hospitalization, and HRQOL?; and 2) can we reliably quantify the expected effect on mortality, hospitalization, and HRQOL that may follow in future HF trials?
METHODS
This study followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guideline (7) . STUDY (9) . For trials with more than 1 exercise intervention arm, we followed the Cochrane Handbook's approach for combining groups (9) . All data was first extracted We calculated commonly reported indicators of surrogate validation (11) . The correlation coefficient 
RESULTS
STUDY SELECTION AND CHARACTERISTICS. A total of 31 studies and 32 comparison groups (1 study had 2 exercise intervention arms [16] ) were included for analysis ( Figure 1) .
A summary of included studies is given in Table 1 (details are listed in Online Table 1 with supplemental references listed). The nature of exercise training varied across studies with regard to the frequency, duration, and intensity of exercise (Online Table 1 ).
RISK OF BIAS. The overall risk of bias assessment was moderate, although several studies failed to give sufficient details to assess risk of bias criteria (Online Table 2 ). Reporting was found to be considerably better in more recently published studies.
IMPACT OF EXERCISE TRAINING. E x e r c i s e c a p a c i t y . EC was reported at follow-up times ranging from 1 to 14 months. In the subset of studies reporting VO 2 peak, there was a larger increase in mean pooled EC with exercise-based CR compared with control 
S u r r o g a t e t h r e s h o l d e f f e c t . Based on the correlation analyses, we estimated STEs for EC and HRQOL.
For the subset of studies reporting VO 2 peak (Figure 2) , we estimated that an average improvement of 5 ml/ kg/min in VO 2 peak exercise-based CR versus control is needed to predict a favorable improvement in HRQOL with exercise-based CR compared to control. For the subset of studies reporting 6MWT (Figure 3) , we estimated an STE of 80 m for 6MWT to predict a significant improvement in MLwHF with exercise-based CR versus control. This pattern of link between EC and final outcomes was consistent across all sensitivity analyses (Online Tables 3 to 6 ).
DISCUSSION
Using trial-level data from RCTs of exercise-based CR for HF, we formally evaluated the evidence for EC as a surrogate endpoint for the final outcomes of mortality, hospitalization, and HRQOL. Our results show an increase in VO 2 peak or 6MWT with exercisebased CR to be associated with improvements in clinical outcomes (24) . However, the observed levels of association indicate EC is a poor surrogate endpoint for mortality and hospitalization and has moderate validity for HRQOL. We found an STE for VO 2 peak of 5 ml/kg/min and 6MWT of 80 m. Thus, exercise-based CR would need to increase VO 2 peak and 6MWT by this level (or more) to have 95% confidence interval to be able to demonstrate significant improvement in HRQOL in a future trial. Whereas a number of studies reported VO 2 peak, a small proportion directly measured VO 2 peak using cardiorespiratory testing, and others predicted VO 2 peak using a submaximal exercise. However, this limitation does not apply to the subgroup of studies that assessed EC using 6MWT. In addition, although Here, we would argue that such heterogeneity is implicit in a systematic review and meta-analysis of a complex intervention such as exercise-based CR (27) . However, it could be argued that restricting our analyses to exercise-based CR trials limits the generalizability of our results. However, it is recommended that the surrogate validation be undertaken in trials across the same intervention (5) . In severe and advanced stages of HF, improvements in independence and the ability to perform daily tasks become even more important than improvements in morbidity and mortality. In this respect, linking increases in EC to HRQOL improvements can be seen as a clinically relevant finding. Exercise Capacity as Surrogate Endpoint in Exercise-Based Rehabilitation for HF
